logo
  • 123-456-7890

Contact Us

Book Your Appointment

Get In Touch

Have a question?

Feel free to leave us your message & we will get back to you

    Contact US - Eyedeology Optometry
    phone Book Now
    phone Book Now
    Rockyview Health Centre, 1011 Glenmore Trail SW Building #1 Suite 423, Calgary, AB T2V 4R6, Canada
    587-353-5061 Book Appointment
    Mission
    We are passionate about your eyes, and about building long-lasting relationships. Our goal is to ensure your eyes remain healthy throughout your life. We are all about service, love, kindness and a belief in strong community. Through our holistic approach to caring for you and our dedication to learning, we pioneer carefully researched new treatments, technology, and products to help ensure eye health.

    Areas We Serve

    phone Call NowBook Now

    Advanced Myopia Control for Children

    Recent randomized controlled clinical trial results presented at the ARVO 2026 Annual Meeting showed promising results for children aged 4–12. Among the 196 children who completed the study, those wearing MiYOSMART iQ showed no average myopia progression after 12 months. The study also found that excessive axial eye growth was reduced to levels below or comparable to those seen in children without refractive errors.

    Designed to Help Control Myopia Progression

    Myopia, commonly known as short-sightedness, can progress during childhood as the eye grows excessively. Managing myopia earlier in life may help reduce the impact of continued progression and the associated risks of high myopia later in life.

    MiYOSMART iQ builds on the established D.I.M.S. Technology used in MiYOSMART lenses and introduces a Triple Enhanced Design (TED). This design incorporates three key enhancements:

    1. Defocus Segments Closer to the Center: The segments are positioned closer to the geometric center of the lens to provide continued exposure to myopic defocus across the near-peripheral retina.
    2. Higher Defocus Power: The lens provides a stronger myopic defocus signal intended to support myopia control.
    3. Extended Treatment Zone: A larger treatment area provides broader coverage of the child’s peripheral visual field, including when larger frames are used.

    Clinical Results Across Different Age Groups

    The clinical trial included children between 4 and 12 years of age, with results demonstrating myopia-control efficacy across the age groups studied.

    For children aged 4–6 years, MiYOSMART iQ demonstrated 65% efficacy in spherical equivalent refractive error (SER) and 44% efficacy in axial length over 12 months. For children aged 7–12 years, the lens demonstrated over 100% efficacy in SER and 94% efficacy in axial length during the same period.

    The study also reported a high level of compliance with daily, all-day wear among children across the age groups studied.

    Built on Established D.I.M.S. Technology

    MiYOSMART iQ represents an evolution of MiYOSMART, a myopia-control lens technology backed by more than 100 peer-reviewed scientific publications. The updated lens design builds on research into how the eye responds to myopic defocus and focuses on delivering a stronger and more consistently positioned defocus signal.

    Since its launch in 2018, more than 15 million MiYOSMART spectacle lenses have been purchased by parents across more than 50 countries worldwide.

    Supporting Earlier Myopia Management

    The clinical findings for MiYOSMART iQ include children as young as four years old, representing an important development in spectacle-lens-based myopia control. Early-onset myopia can progress during a critical period of childhood eye development, making appropriate management an important consideration for children with progressive myopia. MiYOSMART iQ provides an advanced spectacle-lens option for children who require myopia management. An eye care professional can assess your child’s vision and determine whether this type of lens is appropriate for their individual needs.
    587-317-2134